Geode Capital Management
AKBA icon

Geode Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Geode Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.97M Buy
6,452,252
+175,075
+3% +$241K ﹤0.01% 2443
2025
Q4 		$10.1M Buy
6,277,177
+92,226
+1% +$193K ﹤0.01% 2409
2025
Q3 		$16.9M Buy
6,184,951
+110,493
+2% +$368K ﹤0.01% 2088
2025
Q2 		$22.1M Buy
6,074,458
+1,043,718
+21% +$2.87M ﹤0.01% 1906
2025
Q1 		$9.66M Buy
5,030,740
+235,645
+5% +$481K ﹤0.01% 2315
2024
Q4 		$9.11M Buy
4,795,095
+40,631
+0.9% +$70.6K ﹤0.01% 2436
2024
Q3 		$6.28M Buy
4,754,464
+218,172
+5% +$291K ﹤0.01% 2644
2024
Q2 		$4.63M Buy
4,536,292
+2,717,345
+149% +$3.36M ﹤0.01% 2774
2024
Q1 		$3.33M Buy
1,818,947
+17,257
+1% +$27.6K ﹤0.01% 2908
2023
Q4 		$2.23M Buy
1,801,690
+77,416
+4% +$79K ﹤0.01% 3059
2023
Q3 		$1.97M Sell
1,724,274
-48,703
-3% -$62.6K ﹤0.01% 3081
2023
Q2 		$1.62M Buy
1,772,977
+90,479
+5% +$87.3K ﹤0.01% 3178
2023
Q1 		$943K Hold
1,682,498
– – ﹤0.01% 3377
2022
Q4 		$970K Buy
1,682,498
+60,673
+4% +$19K ﹤0.01% 3352
2022
Q3 		$512K Buy
1,621,825
+4,432
+0.3% +$1.74K ﹤0.01% 3712
2022
Q2 		$571K Sell
1,617,393
-1,535,365
-49% -$644K ﹤0.01% 3693
2022
Q1 		$2.26M Sell
3,152,758
-55,231
-2% -$118K ﹤0.01% 3203
2021
Q4 		$7.25M Sell
3,207,989
-21,954
-0.7% -$59.9K ﹤0.01% 2663
2021
Q3 		$9.3M Buy
3,229,943
+307,291
+11% +$877K ﹤0.01% 2498
2021
Q2 		$11.1M Buy
2,922,652
+323,845
+12% +$1.09M ﹤0.01% 2389
2021
Q1 		$8.8M Buy
2,598,807
+374,236
+17% +$1.35M ﹤0.01% 2442
2020
Q4 		$6.23M Buy
2,224,571
+67,953
+3% +$198K ﹤0.01% 2481
2020
Q3 		$5.41M Buy
2,156,618
+54,909
+3% +$482K ﹤0.01% 2344
2020
Q2 		$28.5M Buy
2,101,709
+276,943
+15% +$2.87M 0.01% 1240
2020
Q1 		$13.8M Buy
1,824,766
+166,938
+10% +$1.3M ﹤0.01% 1538
2019
Q4 		$10.5M Buy
1,657,828
+79,006
+5% +$376K ﹤0.01% 1983
2019
Q3 		$6.19M Buy
1,578,822
+79,729
+5% +$342K ﹤0.01% 2254
2019
Q2 		$7.25M Buy
1,499,093
+234,774
+19% +$1.34M ﹤0.01% 2153
2019
Q1 		$10.4M Buy
1,264,319
+252,775
+25% +$1.73M ﹤0.01% 1873
2018
Q4 		$5.59M Buy
1,011,544
+373,594
+59% +$2.92M ﹤0.01% 2152
2018
Q3 		$5.63M Buy
637,950
+52,556
+9% +$470K ﹤0.01% 2278
2018
Q2 		$5.84M Buy
585,394
+35,159
+6% +$352K ﹤0.01% 2233
2018
Q1 		$5.24M Buy
550,235
+48,972
+10% +$685K ﹤0.01% 2207
2017
Q4 		$7.45M Sell
501,263
-54,654
-10% -$906K ﹤0.01% 1953
2017
Q3 		$10.9M Buy
555,917
+227,736
+69% +$3.5M ﹤0.01% 1656
2017
Q2 		$4.71M Sell
328,181
-1,915
-0.6% -$24.3K ﹤0.01% 2182
2017
Q1 		$3.04M Buy
330,096
+14,959
+5% +$146K ﹤0.01% 2413
2016
Q4 		$3.28M Buy
315,137
+6,732
+2% +$58K ﹤0.01% 2329
2016
Q3 		$2.79M Buy
308,405
+80,036
+35% +$680K ﹤0.01% 2347
2016
Q2 		$1.71M Buy
228,369
+7,790
+4% +$68K ﹤0.01% 2576
2016
Q1 		$1.99K Buy
220,579
+73,871
+50% +$599K ﹤0.01% 2467
2015
Q4 		$1.9M Buy
146,708
+19,017
+15% +$194K ﹤0.01% 2521
2015
Q3 		$1.23M Buy
127,691
+5,932
+5% +$54.4K ﹤0.01% 2754
2015
Q2 		$1.25M Buy
121,759
+78,821
+184% +$672K ﹤0.01% 2786
2015
Q1 		$477K Buy
42,938
+2,640
+7% +$28.1K ﹤0.01% 3211
2014
Q4 		$469K Buy
40,298
+4,279
+12% +$61.4K ﹤0.01% 3223
2014
Q3 		$797K Buy
36,019
+6,108
+20% +$140K ﹤0.01% 2923
2014
Q2 		$831K Buy
+29,911
New +$720K ﹤0.01% 2900

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management's AKBA Position: Q1 2026 in Review

Geode Capital Management increased its Akebia Therapeutics (AKBA) stake by 2.8% in Q1 2026, buying an estimated $241K and bringing the position to 6,452,252 shares worth $8.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2443.

Geode Capital Management first reported a position in AKBA in Q2 2014 and has held it in 48 quarters since. The position peaked at $28.5M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Geode Capital Management held 6,452,252 shares of Akebia Therapeutics worth $8.97M as of Q1 2026.
  • Geode Capital Management bought 175,075 Akebia Therapeutics shares in Q1 2026, an estimated $241K.
  • Akebia Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2443 holding.
  • Geode Capital Management first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 48 quarters since.
  • Geode Capital Management's Akebia Therapeutics position peaked at $28.5M in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.